Leukemia, Erythroblastic, Acute clinical trials
The registry lists 175 studies for Leukemia, Erythroblastic, Acute across more than 10 countries. 0 are recruiting or about to start. 7 of them are mainly about Leukemia, Erythroblastic, Acute (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Who runs them
National Cancer Institute (NCI) (43) · Fred Hutchinson Cancer Center (12) · SWOG Cancer Research Network (11) · Case Comprehensive Cancer Center (10) · Roswell Park Cancer Institute (8) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Eastern Cooperative Oncology Group (6) · Alliance for Clinical Trials in Oncology (6)
What is being tested here
Drugs under test in Leukemia, Erythroblastic, Acute studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cytarabine | 0 | 4 | 43 |
| Etoposide | 0 | 3 | 15 |
| Mitoxantrone | 0 | 1 | 14 |
| Gemtuzumab | 0 | 7 | 13 |
| Busulfan | 0 | 1 | 13 |
| Idarubicin | 0 | 1 | 12 |
| Daunorubicin | 0 | 3 | 12 |
| Tipifarnib | 0 | 2 | 11 |
| Fludarabine phosphate | 0 | 0 | 11 |
| Fludarabine | 0 | 0 | 11 |
Drug classes tested here Antimetabolites 66 · Alkylating agents 19 · Calcineurin inhibitors 8 · HDAC inhibitors 7 · Proteasome inhibitors 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 2026Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia · National Cancer Institute (NCI)
Who these studies take
No Leukemia, Erythroblastic, Acute study is recruiting now.
Across all 175 studies, recruiting or not: 34% stop at 75 or younger and 22% at 65; 28% take children; 1% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Leukemia, Erythroblastic, Acute studies take
Of 11 phase 2 interventional studies under Leukemia, Erythroblastic, Acute, half reached primary completion within 63 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 63 mo50–118 · 11 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 175. Browse all 175 → or search them.
- Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingNCT00392353Phase 1/21 country
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT00658814Phase 21 country
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00651261Phase 32 countries
- Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyCompletedNCT02071901Phase 21 country
- Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00093470Phase 33 countries
- Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RCompletedNCT00534469Phase 2
- Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01822015Early Phase 11 country
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 11 country
- Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic CancersTerminatedNCT04083170Phase 21 country
- Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02085408Phase 33 countries
- Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/21 country
- Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT008984561 country
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory AnemiaCompletedNCT00046930Phase 32 countries
- Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00005962Phase 23 countries
- Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01154439Phase 11 country
- Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAMLCompletedNCT04424147Phase 21 country
- Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01555268Phase 11 country
- Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 21 country
- Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT01550185Phase 11 country
- Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 21 country
- Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous LeukemiaWithdrawnNCT00003405Phase 21 country
- Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CRCompletedNCT02497404Phase 21 country
- Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02144675Phase 21 country
- AML Therapy With Irradiated Allogeneic CellsTerminatedNCT02105116Not applicable1 country
- Genetics Study of Tissue Collected From Patients With Acute Myeloid LeukemiaStatus unknownNCT008980921 country
- Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00372593Phase 36 countries
- Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyCompletedNCT01235572Phase 21 country
- Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 11 country
- Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 11 country
- A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 StatusCompletedNCT00462761Phase 12 countries
- Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received ChemotherapyCompletedNCT00509093Phase 21 country
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionCompletedNCT00045435Phase 21 country
- Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003396Phase 21 country
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCompletedNCT00895934Phase 1/21 country
- Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02030405Phase 21 country
- Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01031368Phase 11 country
- Metformin+Cytarabine for the Treatment of Relapsed/Refractory AMLTerminatedNCT01849276Phase 11 country
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 21 country
- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02019069Phase 21 country
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 11 country
- Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005092Phase 11 country
- Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00425477Phase 21 country
- AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01253447Phase 21 country
- Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute LeukemiaTerminatedNCT00245115Phase 11 country
- Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00295841Phase 11 country
- Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00795002Phase 21 country
- Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicable1 country
- Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete RemissionCompletedNCT00070135Phase 21 country
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT01835288Phase 2
- Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid LeukemiaTerminatedNCT01801046Phase 11 country